Literature DB >> 19720812

Sitaxentan-induced hepatic failure in two patients with pulmonary arterial hypertension.

A Lavelle, R Sugrue, G Lawler, N Mulligan, B Kelleher, D M Murphy, S P Gaine.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19720812     DOI： 10.1183/09031936.00058409

Source DB:  PubMed          Journal:  Eur Respir J        ISSN： 0903-1936            Impact factor:   16.671


× No keyword cloud information.
  11 in total

1.  Effectiveness of phosphodiesterase-5 inhibitor therapy for portopulmonary hypertension.

Authors:  Jolene H Fisher; Sindhu R Johnson; Cathy Chau; Amie T Kron; John T Granton
Journal:  Can Respir J       Date:  2014-12-18       Impact factor: 2.409

Review 2.  Treatment of pulmonary arterial hypertension with targeted therapies.

Authors:  Dermot S O'Callaghan; Laurent Savale; David Montani; Xavier Jaïs; Olivier Sitbon; Gérald Simonneau; Marc Humbert
Journal:  Nat Rev Cardiol       Date:  2011-07-19       Impact factor: 32.419

Review 3.  Endothelin and hepatic wound healing.

Authors:  Al-karim Khimji; Don C Rockey
Journal:  Pharmacol Res       Date:  2011-03-21       Impact factor: 7.658

4.  Sitaxsentan-induced acute severe hepatitis treated with glucocorticoid therapy.

Authors:  Marcus Chin; Robert D Levy; Eric M Yoshida; Michaeal F Byrne
Journal:  Can Respir J       Date:  2012 Jan-Feb       Impact factor: 2.409

Review 5.  Chronic kidney disease: a new look at pathogenetic mechanisms and treatment options.

Authors:  Damien Noone; Christoph Licht
Journal:  Pediatr Nephrol       Date:  2013-03-08       Impact factor: 3.714

6.  Leveraging Human Genetics to Identify Safety Signals Prior to Drug Marketing Approval and Clinical Use.

Authors:  Rebecca N Jerome; Meghan Morrison Joly; Nan Kennedy; Jana K Shirey-Rice; Dan M Roden; Gordon R Bernard; Kenneth J Holroyd; Joshua C Denny; Jill M Pulley
Journal:  Drug Saf       Date:  2020-06       Impact factor: 5.606

7.  Regulator of G-protein signaling-5 is a marker of hepatic stellate cells and expression mediates response to liver injury.

Authors:  Arya J Bahrami; Jagadambika J Gunaje; Brian J Hayes; Kimberly J Riehle; Heidi L Kenerson; Raymond S Yeung; April S Stempien-Otero; Jean S Campbell; William M Mahoney
Journal:  PLoS One       Date:  2014-10-07       Impact factor: 3.240

Review 8.  Hotspots and frontiers in pulmonary arterial hypertension research: a bibliometric and visualization analysis from 2011 to 2020.

Authors:  Zhen He; Lei Dai; Yuyue Zuo; Yu Chen; Hongjie Wang; Hesong Zeng
Journal:  Bioengineered       Date:  2022-06       Impact factor: 6.832

Review 9.  Endothelin Blockade in Diabetic Kidney Disease.

Authors:  Lidia Anguiano; Marta Riera; Julio Pascual; María José Soler
Journal:  J Clin Med       Date:  2015-05-25       Impact factor: 4.241

Review 10.  The limits of oral therapy in pulmonary arterial hypertension management.

Authors:  Qian-Qian Liu; Zhi-Cheng Jing
Journal:  Ther Clin Risk Manag       Date:  2015-11-23       Impact factor: 2.423
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.